NasdaqGS - Nasdaq Real Time Price USD

Vir Biotechnology, Inc. (VIR)

5.39

-0.22

(-3.83%)

As of 12:14:30 PM EDT. Market Open.

Q1 2025 Vir Biotechnology Inc Earnings Call

Q1 2025 Vir Biotechnology Inc Earnings Call

Thomson Reuters StreetEvents 2 hours ago

VIR
-3.83%

ALNY
Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

Despite a significant revenue drop, Vir Biotechnology Inc (VIR) maintains a strong cash position and progresses in key therapeutic areas.

GuruFocus.com 8 hours ago

VIR
-3.83%

ALNY
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -6.02% and 84.51%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 17 hours ago

VIR
-3.83%
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

SAN FRANCISCO, May 07, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2025.

Business Wire 20 hours ago

VIR
-3.83%
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

SAN FRANCISCO, April 30, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2025, on May 7, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on May 7, 2025.

Business Wire 7 days ago

VIR
-3.83%
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

SAN FRANCISCO, April 24, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from a 24-week subgroup analysis of its ongoing Phase 2 SOLSTICE trial in chronic hepatitis delta at the upcoming European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam (The Netherlands), May 7-10. The Company will also present 24 Week post-treatment follow-up data from the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran, a

Business Wire 14 days ago

VIR
-3.83%
Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Vir Biotechnology, Inc. (NASDAQ:VIR) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]

Insider Monkey 29 days ago

VIR
-3.83%
Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company

Key Insights Given the large stake in the stock by institutions, Vir Biotechnology's stock price might be vulnerable to...

Simply Wall St. last month

VIR
-3.83%
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

SAN FRANCISCO, March 13, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the efficacy and safety of tobevibart in combination with elebsiran in people living with chronic hepatitis delta (CHD). ECLIPSE 1, the first trial of the program to be initiated, and ECLIPSE 2 are Phase 3 trials designed to provide the registrational data needed for submi

Business Wire last month

VIR
-3.83%
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results

Vir Biotechnology, Inc. ( NASDAQ:VIR ) defied analyst predictions to release its annual results, which were ahead of...

Simply Wall St. 2 months ago

VIR
-3.83%
Q4 2024 Vir Biotechnology Inc Earnings Call

Q4 2024 Vir Biotechnology Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

VIR
-3.83%

SNY

ALNY
Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

Vir Biotechnology Inc (VIR) showcases progress in oncology and infectious disease programs while managing financial hurdles and operational restructuring.

GuruFocus.com 2 months ago

VIR
-3.83%
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates

Vir Biotechnology (VIR) delivered earnings and revenue surprises of 10.59% and 15.22%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

VIR
-3.83%
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

SAN FRANCISCO, February 26, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2024.

Business Wire 2 months ago

VIR
-3.83%
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

SAN FRANCISCO, February 19, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 8:50 a.m. PT / 11:50 a.m. ET in Boston, Massachusetts.

Business Wire 2 months ago

VIR
-3.83%
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

SAN FRANCISCO, February 12, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2024, on February 26, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on February 26, 2025.

Business Wire 2 months ago

VIR
-3.83%
Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Vir Biotechnology, Inc. (NASDAQ:VIR) stands against the other stocks that are skyrocketing now. The market has started to favor smaller companies in 2025, and stocks between $1 billion and […]

Insider Monkey 3 months ago

VIR
-3.83%
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

On Wednesday, Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome, maximum tolerated dose not yet reached as dose escalation continues, and early clinical respon

Benzinga 3 months ago

VIR
-3.83%
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates

Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.

Zacks 3 months ago

VIR
-3.83%
Vir Biotechnology Reports Promising Trial Results for Cancer Therapies

Vir Biotechnology ( (VIR) ) has issued an update. Vir Biotechnology announced promising Phase 1 trial results for its dual-masked T-cell engagers, VIR-5818 and VIR-5500, targeting HER2-expressing solid tumors and PSMA in metastatic castration-resistant prostate cancer respectively. The data showed compelling early clinical responses and a favorable safety profile, with no dose-limiting toxicities and no severe cytokine release syndrome observed. The findings support the potential of Vir’s PRO-XT

TipRanks 3 months ago

VIR
-3.83%

Performance Overview

Return	VIR	S&P 500 (^GSPC)
YTD	-26.50%	-2.92%
1-Year	-43.45%	+10.06%
3-Year	-75.00%	+38.47%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Vir Biotechnology, Inc. (VIR)

Q1 2025 Vir Biotechnology Inc Earnings Call

Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results

Q4 2024 Vir Biotechnology Inc Earnings Call

Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates

Vir Biotechnology Reports Promising Trial Results for Cancer Therapies

Performance Overview